Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Turning into a Distributed Writer: My Composing Process - 2See as Your #1: These Low-Sugar Food sources You Ought to Attempt
- 3Well known SUVs With Low Energy Utilization In 2024 vote
- 4Artemis II astronauts will see parts of the moon no human has before. Here’s how
- 5Best Amusement Park in Asia: Which One Is a Must-Visit
- Undeniably popular Historical centers: Where Craftsmanship and History Meet
- Clocks to go forward one hour in Europe as summer time starts
- Why ordering takeout or calling the dog walker might lead to a happier relationship
- ISS astronauts spy airglow and dwarf galaxy | Space photo of the day for Jan. 13, 2026
- Ringleader of suspected human trafficking network arrested in Ethiopia
- Winona Ryder didn't take the 'Stranger Things' plot lightly. How 'otherworldly' grief and a kidnapping in her hometown informed her character.
- Find the Marvels of the World with These Travels
- Scaling New Levels: Rock Climbing Spots On the planet
- Let them eat (Taylor Swift) cake: The baker turning A-listers into life-size desserts
